Events

Science37: The Operating System that enables Hybrid/Agile Clinical Trials: Accelerating Timelines & Optimizing Cost Savings

June 21, 2022

The traditional clinical trial model has not changed significantly in > 60 years. This event will feature how Science37’s decentralized clinical trials model is disrupting the traditional model by enabling Sponsors to achieve a shorter trial start-up, accelerated patient enrollment, better retention, and more diverse participants resulting in maximized time and cost savings to accelerate breakthrough clinical research.…

Read More

Cidara Therapeutics: Research & Development Day

June 17, 2022

The virtual R&D day will feature a panel discussion with Key Opinion Leaders (KOLs) in oncology Ezra Cohen, MD, FRCPSC, FASCO (San Diego Center for Precision Immunotherapy), Perry Nisen, MD, PhD (CEO and Executive Chairman of Quanta), and with Les Tari, PhD (Cidara’s Chief Scientific Officer). The discussion will be focused on Cidara’s Cloudbreak® platform which couples potent inhibitors to…

Read More

Oncocyte: Expert Webinar on the role of DetermaIO and the Tumor Microenvironment in Clinical Practice

June 15, 2022

The webinar will feature presentations from Key Opinion Leaders (KOLs) Chiara Cremolini, MD, PhD (Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy) and Adam Brufsky, MD, PhD (University of Pittsburgh School of Medicine). Dr. Cremolini will provide an expert data overview on the ASCO 2022 poster session: An immune-related gene expression profile to…

Read More

Mesoblast Key Opinion Leader Event Series for Investors & Analysts: Chronic Low Back Pain due to Degenerative Disc Disease

June 13, 2022

The webinar will focus on the current treatment landscape and unmet medical need for patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with local inflammation in the disc. The webinar will feature presentations from Key Opinion Leaders (KOLs) Douglas P. Beall, MD, FIPP, FSIR, DAAPM (Clinical Radiology Oklahoma) and Hyun W. Bae,…

Read More

Recce Pharmaceuticals’ Expert KOL Webinar: How R327 is leading the way as a potential, robust solution to Sepsis and Superbugs

June 2, 2022

The event will feature a presentation from Key Opinion Leader Thomas Heymann (President & CEO of Sepsis Alliance, USA), who will discuss the current treatment landscape and unmet medical need in treating patients with sepsis. Sepsis patient advocate Mary Millard (International Speaker, Hospital Infections & Prevention) will speak about her journey, the unmet need, and the current standard of…

Read More

Please join us for the third episode in ASLAN Pharmaceuticals’ A4 webinar series, Aspects of Atopic Dermatitis and ASLAN004

June 2, 2022

This third and final webinar in ASLAN’s A4 webinar series, “Dialogues with International Thought Leaders in Dermatology” will feature a presentation by Key Opinion Leader (KOL), Peter A Lio, MD, Clinical Assistant Professor at Northwestern University, who will share examples of patient journeys in atopic dermatitis (AD) and highlight the unmet medical needs, patient co-morbidities and limitations…

Read More

Cantargia R&D Day on nadunolimab

June 2, 2022

Join us for the Cantargia R&D Day, featuring presentations from two renowned oncology experts. Prof Eric Van Cutsem, MD, PhD (University Hospitals Gasthuisberg/Leuven & KU Leuven) and Dr Luis Paz-Ares (Hospital Doce de Octubre/National Oncology Research Center/President Oncosur Foundation) will discuss the current treatment landscape and unmet medical need in treating patients with pancreatic ductal adenocarcinoma (PDAC) and non-small…

Read More

PolyPid KOL Webinar on the Cost of Surgical Site Infection

June 2, 2022

The webinar will feature presentations from Key Opinion Leaders (KOLs), Kyle Cologne, MD (Los Angeles County General – USC Medical Center), who will provide a general hospital perspective on the cost of managing surgical site infections (SSIs)  and Elliot Goodman, MD (Mount Sinai Health System), who will discuss the impact SSIs have on quality measures and performance from an…

Read More

Update on Sermonix’s Elaine Phase 2 Clinical Programs

June 2, 2022

The event will feature presentations from Key Opinion Leaders (KOL’s) Sarah Sammons, MD (Duke University) and Senthil Damodaran, MD, PhD (MD Anderson Cancer Center) who will discuss lasofoxifene, Sermonix’s investigational treatment for metastatic breast cancer with an acquired estrogen receptor 1 (ESR1) mutation. Dr. Sammons will provide an overview of the Elaine-1 study, an open-label, randomized, multicenter study evaluating the activity of lasofoxifene versus fulvestrant…

Read More

Fireside Chat with Nuvasive (NASDAQ: NUVA)

June 2, 2022

Focus on NuVasive’s strategic growth plan, including the Company’s less invasive spine product portfolio, new product introductions and globalization strategy Discuss the Company’s expansion in Cervical products and the role of enabling technologies, including the recent launch of the Pulse platform Understand how NuVasive prioritizes and manages product innovation and R&D spending complemented by M&A…

Read More